More SARS-CoV-2 antibodies and antigens
We are now able to provide a wider selection of SARS-CoV-2 recombinant antigens to support the IVD test manufacturers. These antigens are produced in mammalian CHO cells, thus providing excellent performance and allowing post-translational modifications, such as glycosylation and phosphorylation. They can be used with Medix Biochemica’s well validated anti-IgG, anti-IgM, and anti-IgA antibodies in serological testing to detect SARS-CoV-2 antibodies from blood samples.
Recombinant SARS-CoV-2 antigens:
- Nucleocapsid (N)
- Spike S1
- Spike RBD 1 (aa 331-524)
- Spike RBD 2 (aa 319-541)
Serological anti-human IgG, IgM, and IgA antibodies
Rapid detection of anti-IgG, anti-IgM, and anti-IgA antibodies will add value to the diagnosis and treatment of COVID-19 disease, as well as to epidemiological studies on the prevalence of the disease in a population. It has been shown that IgM and IgA become detectable around 1-5 days after onset of symptoms, whereas IgG becomes detectable later, approximately after 8 days.
According to the latest study findings, the IgA response appears and grows early, peaks at week 3 and is even more persistent than the IgM response in Covid-19 patients.
Ref: Padoan, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta (2020) 507:164-166. www.ncbi.nlm.nih.gov
Please see details of Medix Biochemica’s mouse IgG antibodies specific to human IgG, IgM, and IgA: www.medixbiochemica.com.
Lee Biosolutions products
In addition, we support Covid-19 related test development by providing native control proteins and biological specimens, including:
- Control material proteins for IgG, IgM and IgA
- Rheumatoid Factor concentrate used in interference studies
- Biological products including confirmed COVID-19 positive serum
Please visit www.leebio.com to find more information about these products.